Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198
Latest Information Update: 07 Jan 2025
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Jan 2025 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 Planned End Date changed from 1 Oct 2023 to 1 Dec 2023.
- 11 Jan 2022 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.